Historical Stock Chart
5 Years : From Sep 2012 to Sep 2017
Exelixis, Inc. (NASDAQ:EXEL) will release its first quarter 2012
financial results on Thursday, May 3, 2012, after the markets close. The
announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00
p.m. PDT. During the webcast, Exelixis management will discuss the
Company’s financial results, financial outlook and development program
and plans for cabozantinib, and also provide a general business update.
The webcast may be accessed in the Event Calendar page under Investors
An archived replay of the webcast will be available on the Event
Calendar page under Investors at http://www.exelixis.com
and via phone until 11:59 p.m. EDT on June 3, 2012. Access numbers for
the phone replay are: 888-286-8010 (domestic) and 617-801-6888
(international); the passcode is 33847783.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on
cabozantinib (XL184), its most advanced product candidate, in order to
maximize the therapeutic and commercial potential of this compound.
Exelixis believes cabozantinib has the potential to be a high-quality,
broadly-active, differentiated pharmaceutical product that can make a
meaningful difference in the lives of patients. Exelixis has also
established a portfolio of other novel compounds that it believes have
the potential to address serious unmet medical needs, many of which are
being advanced by partners as part of collaborations. For more
information, please visit the company's web site at http://www.exelixis.com.